Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Medicare's Bridge program launched July 1, offering Wegovy, Zepbound, and Foundayo at a $50 monthly out-of-pocket cost for beneficiaries meeting specific BMI thresholds and chronic-condition criteria.
- The Trump administration canceled the planned "Balance" program that would have fully integrated GLP-1 therapies into Medicare Part D, and extended Bridge through December 2027 instead.
- Bridge eligibility requires detailed documentation, prior authorizations, appeals, and ongoing navigation of evolving coverage rules, with administrative workload often rivaling the clinical work itself.
- Some private practices may decline Bridge participation as unsustainable, instead directing patients to manufacturer support programs, specialty obesity clinics, or telehealth services.
- Jeffrey Millstein, an internist and regional medical director at Penn Medicine, argues simplification of eligibility, documentation, prior authorization, and drug pricing is needed for the program to deliver on its promise.
Why it matters: The $50 price point may attract patients, but the eligibility checklist and documentation load on already-strained primary care clinics could create a two-tier system where only patients with health literacy and persistent advocacy cross the Bridge successfully. With Balance canceled and Bridge now running through December 2027, GLP-1 access depends on whether overextended practices can absorb the administrative burden.
Ask SkimNews
